Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma, Sonic AI
Home
/
A Cheeky Pint
/
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
A Cheeky Pint
Notify me
•
Nov 11, 2025
•
2:06:40
Interview
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Dave Ricks
(CEO, Eli Lilly, guest)
Get the full transcript next time A Cheeky Pint releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Eli Lilly, the world's most valuable pharmaceutical company, is heavily investing in technology, building a proprietary on-premise supercomputer with NVIDIA to accelerate AI-driven drug discovery.
The company's growth is overwhelmingly driven by its GLP-1 drugs for diabetes and weight loss, which now constitute the majority of its business and economic value.
Lilly is disrupting the traditional pharmaceutical distribution model with its Lilly Direct platform, selling drugs directly to consumers and creating a multi-billion dollar revenue channel.
The company employs a hybrid R&D strategy, combining the scale of a large pharma company with the agility of smaller, independent research hubs to foster innovation.
Continue your research
Keep pulling the thread on Dave Ricks.
AI and Supercomputing in Drug Discovery
Dominance of GLP-1s and Direct-to-Consumer Strategy
Hybrid R&D and Innovation Models
Or ask anything across 400+ expert conversations
12
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
12
Related
Loading transcript...
Processed May 4, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini